FOXR2 and ependymoma: After histopathological re-evaluation and classification according to the WHO 2021 classification the tumours were divided into the following groups: High-grade glioma (HGG), n = 25 (35%), AT/RT, n = 8 (11%), CNS NB-FOXR2, n = 7 (10%), ETMR, n = 6 (8%) and ependymoma, ZFTA-fusion positive, n = 6 (8%) (Fig. 1A).